Berlin Heals Holding AG has developed the C-MIC device, an implant for heart failure patients. The patented technology, which is easily implantable, delivers a continuous electrical microcurrent to the heart. This helps improve inflammatory parameters in heart tissue and removes excess fluid from the heart.
So far, 35 C-MICs have been successfully implanted in a randomized study, confirming excellent data from a previous pilot study with 10 patients. Follow-up with pilot study patients over three years showed all patients remain in NYHA class 1, achieve around 400 meters in the 6-minute walk test (6MWT), and report high levels of well-being. Approximately CHF 40 million has been invested in the technology’s development and market approval. Berlin Heals expects CE certification by late 2025 or early 2026. Due to the device’s success, the FDA is particularly encouraging its approval in the USA, recognizing the C-MIC as a potential game changer in heart failure treatment.
As reported by Medical Buyer, Marko Bagaric, CEO of Berlin Heals Holding AG, stated that the C-MIC device could significantly improve the quality of life and extend life expectancy for many heart failure patients worldwide. He expressed confidence that the C-MIC would set a new standard in treatment, with patients feeling better within weeks after a brief operation and experiencing a continuous, imperceptible microcurrent flow.